List view / Grid view
Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, and Life Technologies Corporation (NASDAQ: LIFE), a leading life sciences company, have signed a definitive agreement under which Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share, or approximately $13.6 billion, plus the…
15 April 2013 | By Roche
Roche and Ascletis have entered into a collaboration...
11 April 2013 | By Roche
Group sales increase 6% at CER1 to 11.6 billion Swiss francs...
11 April 2013 | By Sanofi
A pivotal milestone in the fight against malaria...
10 April 2013 | By Pfizer
Palbociclib has received Breakthrough Therapy designation...
Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure (HF). The test was developed in partnership with BG Medicine, Inc., (NASDAQ: BGMD) to run on Abbott’s ARCHITECT immunochemistry platform.
10 April 2013 | By Merck
Merck is seeking FDA approval of NOXAFIL...
10 April 2013 | By Bristol-Myers Squibb Company
Creation of the Morehouse School of Medicine/Bristol-Myers Squibb Foundation Partnership...
9 April 2013 | By Novo Nordisk
The first-ever Diabetes Forum takes place in Mexico City (9th April), to address the critical diabetes challenge the country is facing...
9 April 2013 | By researchsea.com
GlaxoSmithKline and A*STAR’s Institute of Chemical and Engineering Sciences have signed a five-year strategic agreement...
8 April 2013 | By Gilead Sciences
Sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus infection...
8 April 2013 | By Teva Pharmaceutical Industries Ltd.
Teva-Handok announced the appointment of Yoo Suk Hong as the first Chief Executive Officer of the business venture...
8 April 2013 | By Merck
VICTRELIS® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection...
8 April 2013 | By Amgen
Amgen supports the direction WHO is taking...
8 April 2013 | By Daiichi Sankyo
GHIT Fund aims to promote the R&D of new medicines, vaccines & diagnostics in Japan...
